“Advancing the Boundaries of High Parameter Flow Cytometry”, 15 minute product talk
Robert Balderas, VP Market Development, BD Biosciences
Flow Cytometry, the tool of the trade of today’s immunologists, is a highly multi-parametric platform, capable of high speed quantitative assessment of cells and other particles, at the single cell level. Flow cytometry has been a precursor to the current day multi-omic approaches as it is among the early experimental approaches that allowed simultaneous measurements of two, three, four and currently up to 30+ parameters.on the same cells. The field of high parameter flow cytometry includes multiple major areas of development including receptor expression, the instrument, affinity reagents, new dyes and flurochromes, application development, software and bioinformatics. The integration of flow cytometry to basic, clinical and translation biomedical research will be significantly enhanced with the development of the new Sirigen dyes off the Blue, Green, Violet, UV and deep UV which have been integrated in BD High Parameter solution. Since the introduction of the BD FACSymphony high parameter flow cytometer, we have an unprecedented knowledge and understanding of how interaction between cell surface molecules, kinases and transcription factors are regulated. Thus, resulting in deeper understanding of cancer biology, better vaccine development and drug discovery strategies. This talk will spotlight how BD and our community of users are continuing to innovate at the level of high parameter flow cytometry by sharing some of the advancements and insights in our continued efforts to bring tools of discovery.
Dr. Balderas has 40 years of leadership experience in both academia and the biotechnology industry. As a corporate scientist, site manager, and marketer in the field of biotechnology. Currently as, VP of Biological Sciences, he is focused on accelerating market adoption of new tools and technologies into the Life Science Community. Robert has championed multiple key successful product launches during his tenure at Pharmingen and BD Biosciences and is recognized for his success in creating collaborations with scientists to generate products that are relevant to customers for which he has been honored twice with the prestigious BD Howe Award for “Sensing Sourcing and Seeking New Technologies for the advancement of Technologies for product success.” Robert has a rich academic background having worked in the field of autoimmunity at Scripps Research Institute which he further enhanced with an MBA from University of San Diego. Robert has been the architect and pioneer of the BD Horizon tour and the biology and Technology Champion for the BD FACS Symphony platform. Robert serves in various editorial boards and is a board member at FOCIS; a member of Dean’s council at UCSD School of Biological Sciences to name a select few. He leads various academic-industry collaborations and has over 75 scientific publications and is leader who truly motivates his technical team and fosters collaboration to ensure program success.
“Increase confidence in your data by leveraging innovative technologies”, 15 minute product talk
Dr. Alina Lelic, Field Applications Scientist
We will discuss data standardization with products and workflows designed to increase consistency and reproducibility across all experiments.
Alina joined Beckman in 2017 as a Field Applications Scientist. Prior to joining Beckman Alina was a post-doctoral fellow at McMaster University and also managed an immune monitoring facility at Human Immune Testing Suites.
“Simultaneous Proteomics and Transcriptomics: TotalSeq™ and The Future of Single Cell Analysis”, 15 minute product talk
De Novo Software
“What’s new in FCS Express Version 7”, 15 minute product talk
Dr. David Novo
David received his PhD in Biophysics from UCLA. His research concentrated on developing novel optical and mathematical techniques for measurements and analysis of localized fluorescent Calcium transients from a microdomain within a muscle cell. David also built several confocal microscopes, as well as writing the data acquisition and data analysis systems. Prior to commencing his PhD, David worked with Dr. Howard Shapiro, one of the leaders in the field of flow cytometry, performing research on membrane potential determination in bacteria using flow cytometry. During the course of this research they built several flow cytometers custom made for bacterial measurements. Two papers were published on the subject. David still maintains close ties to the flow cytometry community through his appointment to the Data Standards Committee of the International Society of Analytical Cytometry. This committee maintains the flow cytometry data file standard and deals with issues standardizing all sorts of flow cytometry related data storage and analysis issues. David frequently consults on data analysis issues related to flow cytometry and collaborates on many projects involving novel data analysis requirements.
“The CellStream® image-based flow cytometer: Technical specifications, performance characteristics, and novel applications”, 15 minute product talk
Matthew Rodrigues, PhD, Research Scientist
This talk provides a brief overview of the technical specifications of the CellStream®, discusses performance characteristics, and shows initial results of novel and traditional flow cytometry applications.
“Functional Genetic Screens using Next-generation Sequencing and High-throughput Flow Cytometry”, 25 minute end user presentation
David Chen, Ph.D., Assistant Professor, Systems Biology & Director, Division of Epigenetics and Transcriptional Engineering, Beckman Research Institute – City of Hope National Medical Center
Identification of novel functional elements in the human genome represents an attractive therapeutic opportunity for malignant diseases. For this, we developed a high-density CRISPR mutagenesis strategy to investigate several cancer driver genes in MLL-rearranged leukemia. Combining the next-generation sequencing (NGS) and high-throughput flow cytometry, we revealed the potential of this platform to identify and validate novel functional regions in mammalian genes. Furthermore, when coupling with the patient sequencing databases and protein structural modeling, this high-throughput functional genomics approach facilitates the discovery of therapeutic-relevant mutants in the human population. We foresee a general application of this pipeline to speed-up the therapeutic target discovery.
Dr. Chun-Wei David Chen obtained his Ph.D. degree at the University of Rochester and received his postdoctoral training at Harvard Medical School. Prior to joining the City of Hope in 2017, Dr. Chen served as a Senior Research Scientist at Memorial Sloan-Kettering Cancer Center and an Instructor at Dana-Farber Cancer Institute/Harvard Medical School. Dr. Chen’s laboratory in the Department of Systems Biology at the City of Hope is focused on using high-throughput functional genetic screens to dissect the mechanisms underlying the therapeutic resistance in cancers. His research program is currently supported by several NIH (R00, R37, R01) and foundation (ASH, LLS) awards.